Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies

Table 1 Eptinezumab Clinical Studies

Study	Description	Migraine Diagnosis	Dosing Frequency	Follow-up Visits
NCT01772524 [22]	Phase 1b DB/PC/PG/R	EM	1000 mg, placebo Single dose (day 0)	Weeks 4, 8, 12, 24
NCT02275117 [23]	Phase 2 DB/PC/PG/R	CM	10, 30, 100, 300 mg, placebo Single dose (day 0)	Weeks 4, 8, 12, 24, 36, 49
PROMISE-1 (NCT02559895) [24]	Phase 3 DB/PC/PG/R	EM	30, 100, 300 mg, placebo Four doses (day 0, weeks 12, 24, 36)	Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48, 56
PROMISE-2 (NCT02974153) [25]	Phase 3 DB/PC/PG/R	CM	100, 300 mg, placebo Two doses (day 0, week 12)	Weeks 2, 4, 8, 12, 16, 20, 24, 32

ISSN: 1129-2377